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Objectives: We have recently reported that spontaneously hypertensive rats (SHR) present a contextual fear
conditioning (CFC) deﬁcit. This deﬁcit is improved by antipsychotic drugs, potentiated by proschizophrenia
manipulations and not altered by acute administration of carbamazepine, lamotrigine and valproic acid.
Nevertheless, the effects of lithium—a classical mood stabilizer—or repeated treatment with these drugs were
not evaluated. The main aim of the present study was to extend our previous work by investigating a possible
beneﬁcial effect of acute and/or chronic treatments with lithium or lamotrigine on the acquisition deﬁcit of
CFC presented by SHR.
Methods: Rats were submitted to CFC task after an acute treatment with lithium and/or a repeated treatment
with lithium and lamotrigine.
Results: Our data revealed that the CFC deﬁcit presented by SHR is not improved by acute or repeated
treatment with lithium. Repeated lamotrigine treatment potentiated the deﬁcit presented by SHR and
impaired CFC in control animals (Wistar Rats).
Conclusions: These data reinforce the absence of beneﬁcial effects of mood stabilizers on the emotional
context processing impairment modeled by SHR.
© 2011 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
Psychiatric disorders, including schizophrenia, bipolar disorder and
attention deﬁcit/hyperactivity disorder (ADHD), are associated with
impairments in emotional processing (Addington andAddington, 1998;
Marsh and Williams, 2006; Phillips et al., 2003). In rodents, fear
conditioning is extensively used to investigate the biological basis of
emotion (LeDoux, 2000; Pezze and Feldon, 2004). In this paradigm, an
emotionally neutral conditioned stimulus (e.g., contextual stimulus) is
paired with an aversive unconditioned stimulus, e.g., a foot shock,
during the acquisition phase. As a result, the contextual stimulus comes
toelicit conditioned fear responseduring expressionphase,without foot
shock presentation, because it acquires aversive reinforcing properties
(LeDoux, 2000; Pezze and Feldon, 2004). While fear is an adaptative
component of response to aversive stimuli, inappropriate fear responsesRats; CFC, Contextual fear
order; WR, Wistar rats.
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diminished or exaggerated emotional response to aversive stimuli may
be observed in schizophrenia, ADHD, and bipolar disorder (Addington
and Addington, 1998; Marsh and Williams, 2006; Phillips et al., 2003)
and may trigger nonadaptative responses like suicide (Kohler and
Martin, 2006).
We have recently reported that spontaneously hypertensive rats
(SHR) present a deﬁcit in contextual fear conditioning (CFC) that is
reverted by antipsychotics but not by acute treatment with mood
stabilizers or psychostimulants (used to treat bipolar disorder and
ADHD, respectively). In addition, this deﬁcit is potentiated by
pharmacological (ketamine and amphetamine) and environmental
manipulations (sleep deprivation) that enhances psychosis in patients
(Becker et al., 2003; Herz and Melville, 1980; Janowsky and Risch,
1979). Based on these ﬁndings, we suggested that the deﬁcit in CFC
presented by SHRcould be a useful animalmodel to study abnormalities
in emotional context processing related to schizophrenia (Calzavara
et al., 2009).
However schizophrenia and bipolar disorder share some therapeutic
management: both are treated with atypical antipsychotics. In our
previous study (Calzavara et al., 2009),we evaluated the acute effects of
somemood stabilizers—carbamazepine, lamotrigine and valproic acid—
but we did not test lithium. In this respect, lithium has been in use in
medicine for decades and has been tried and tested across the full range
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stabilizer of all and, because of its unique properties, it may even
constitute a class of its own (Malhi et al., 2009). Moreover, although
acute treatment with mood stabilizers is effective in a series of animal
models (Arban et al., 2005; Corrêa et al., 2007; Lamberty et al., 2001),
clinical trials suggest that the therapeutic effect is better observed after
long-term treatment (reviewedbyAmannet al., 2007; Fountoulakis and
Vieta, 2008). Speciﬁcally related to lithium and lamotrigine, some
placebo-controled studies have shown that there is no acute effect of
lamotrigine (reviewed by Bowden, 2002), and lithium seems to be
moderately efﬁcacious for acute bipolar depression (Van Lieshout and
MacQueen, 2010).
Based on the above, the aim of the present study was to extend the
pharmacological characterization of the CFC deﬁcit presented by SHR
by evaluating a possible beneﬁcial effect of acute treatment with
lithium and/or of long-term treatment with lithium or lamotrigine.
Based on the described antinociceptive action of lamotrigine (Gilron
et al., 2006; Munro et al., 2007) we also veriﬁed the effects of
lamotrigine on sensitivity to the shock. In addition, we evaluated the
effects of this drug on locomotion.
2. Material and methods
2.1. Subjects
Male adult (ﬁve-month-old) Wistar Rats (WR) and SHR of our own
colony were housed under conditions of controlled temperature
(22–23 °C) and lighting (12/12 h light/dark cycle, lights on at
07:00 am). Groups of 5–6 animals were kept in Plexiglas cages
(41×34×16.5 cm), with free access to food and water. The animals
weremaintained in accordancewith the guidelines of theCommittee on
Care and Use of Laboratory Animal Resources, National Research
Council, USA. This study was approved by the Ethical Committee of
Federal University of Sao Paulo.
2.2. Drugs
Lithium (Li2CO3, Eurofarma – São Paulo, Brasil) and lamotrigine
(Torrent – São Paulo, Brazil) were diluted in 0.9% saline. Salinewas used
as control solution. All the solutions were injected intraperitoneally in a
volume of 1 ml/Kg of body weight. The doses and schedules used in
these experiments were chosen based on previous studies showing the
mood stabilizer effect of the drugs in animal models (Arban et al., 2005;




On the ﬁrst day (training session), the rats were individually
placed in a dark chamber with a grid ﬂoor (22×22×22 cm). After
150 s, 0.4 mA foot shocks lasting 5 s were applied every 30 s for the
subsequent 150 s. Thirty seconds after the last foot shock, the animal
was removed from the apparatus. The contextual conditioning test
(test session) was performed 24 h after the training. Each animal was
placed in the same dark chamber, without receiving foot shocks. The
freezing duration (deﬁned as complete immobility of the animal with
the absence of vibrissae movements and snifﬁng) was scored during
5 min.
2.3.2. Sensitivity to the shock
Rats were individually placed in a dark chamber with a grid ﬂoor
(22×22×22 cm). After 150 s, 0.4 mA foot shocks lasting 5 s were
applied every 30 s for the subsequent 150 s. The freezing duration
(deﬁned as complete immobility of the animal, with the absence of
vibrissae movements and snifﬁng) was quantiﬁed during 5 min.2.3.3. Locomotor activity
Rats were individually placed in an open-ﬁeld (97 cm in diameter
and 32.5 cm high, with an open top and a ﬂoor divided into 19 similar
parts) and the number of ﬂoor squares entered were quantiﬁed
during 10 min (locomotion frequency).
Each animal was used in only one experiment. All the experiments
were performed between 2:00 and 6:00 pm. All the behavioral
parameters were hand-scored by blinded observers.
2.4. Experimental design
2.4.1. Experiment 1 – Effects of acute treatment with lithium on the CFC
of WR and SHR
WR and SHR (n=6) were treated with 47.5 mg/kg lithium or
saline, twice a day. Sixty minutes later, the animals were submitted to
the training session of the CFC task.
2.4.2. Experiment 2 – Effects of repeated treatment with lithium on the
CFC of WR and SHR
WR and SHR (n=6) were treated with 47.5 mg/kg lithium or
saline, twice a day. This treatment was performed during 7 days. Sixty
minutes later after the second injection on the 7th day, the animals
were submitted to the training session of the CFC task. The duration of
this treatment was determined based on previous works showing that
a seven-day treatment with lithium is able to attenuate the behavioral
alterations and the increase in oxidative stress and mitochondrial
dysfunction presented in an animal model of mania (Corrêa et al.,
2007; Frey et al., 2006).
2.4.3. Experiment 3 – Effects of repeated treatment with lamotrigine on
the CFC of WR and SHR
WR and SHR (n=9–10) were treated with saline or 20 mg/kg
lamotrigine during 20 days. Thirtyminutes after the last injection, rats
were submitted to the training session of the CFC task. The duration of
this treatment was determined based on a previous work showing
that a similar treatment (28 days) with lamotrigine is able to
attenuate the increase in oxidative stress observed in an animal
model of depression (Eren et al., 2007).
2.4.4. Experiment 4 – Effects of lamotrigine on the foot shock sensitivity
Reactivity to the shock was evaluated in the same apparatus used
for fear-conditioning training. WR and SHR (n=10) were treated
with saline or 20 mg/kg lamotrigine. After thirty minutes, rats were
submitted to the training session of the CFC task. After each shock
presentation, freezing time, jump (withdrawal of three or four paws
from the grid ﬂoor) and ﬂinch (withdrawal of one paw from the grid
ﬂoor) were quantiﬁed.
2.4.5. Experiment 5 – Effects of lamotrigine on locomotion
WR and SHR (n=10) were treated with saline or 20 mg/kg
lamotrigine. Thirty minutes later, rats were submitted to the open-
ﬁeld for quantiﬁcation of locomotion.
2.5. Statistical analysis
Datawere analyzed by two-way ANOVA followed by Duncan's test.
The pb0.05 was used as a criterion for statistical signiﬁcance.
3. Results
3.1. Experiment 1 – Effects of acute treatment with lithium on the CFC of
WR and SHR
The freezing time observed after an acute treatment with lithium
is depicted in Fig. 1. Two-way ANOVA revealed a signiﬁcant strain
effect [F(1,20)=20.02; pb0.05]. Post hoc analysis revealed that the
Fig. 2. Freezing response (s) of Wistar Rats (WR) and Spontaneously Hypertensive Rats
(SHR) treated twice a day with injections of saline (SAL) or 47.5 mg/kg lithium (LI)
during seven days. #pb0.05 compared toWR of the same treatment. Two-way analysis
of variance followed by Duncan's test. Data are reported as mean±SE.
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compared toWR group treated with saline or lithium. Lithium did not
modify the freezing response of both strains when compared to the
respective saline groups.
3.2. Experiment 2 – Effects of repeated treatment with lithium on the CFC
of WR and SHR
The freezing time observed after a repeated treatment with
lithium is depicted in Fig. 2. Two-way ANOVA revealed a signiﬁcant
strain effect [F(1,20)=16.78; pb0.05]. Post hoc analysis revealed that
the freezing response was signiﬁcantly reduced in SHR group when
compared toWR group treated with saline or lithium. Lithium did not
modify the freezing response of both strains when compared to the
respective saline groups.
3.3. Experiment 3 – Effects of repeated treatment with lamotrigine on the
CFC of WR and SHR
The freezing time observed after a repeated treatment with
lamotrigine is depicted in Fig. 3. Two-way ANOVA revealed signiﬁcant
strain [F(1,35)=163.20;pb0.05] and treatmenteffects [F(1,35)=10.17;
pb0.05]. Post hoc analysis revealed that the freezing response was
signiﬁcantly reduced in SHR groupwhen compared toWR group treated
with saline or lamotrigine. Repeated lamotrigine treatment decreased
the freezing response in both strains when compared to the respective
saline groups.
3.4. Experiment 4 – Effects of lamotrigine on the foot shock sensitivity
The shock sensitivity parameters observed after a treatment with
lamotrigine is displayed in Table 1. For freezing time, two-way ANOVA
revealed a signiﬁcant strain effect [F(1,36)=5.979; pb0.05]. Post hoc
analysis revealed that the freezing response was signiﬁcantly reduced
in SHR group when compared to WR group treated with saline. For
jump, two-way ANOVA did not reveal any signiﬁcant effect. For ﬂinch,
two-way ANOVA revealed signiﬁcant strain effect [F(1,36)=12.945;
pb0.05] and an interaction between strain and treatment factors
[F(1,36)=6.204; pb0.05]. Post hoc analysis revealed that the ﬂinch
response was signiﬁcantly reduced in SHR group when compared to
WR group treated with saline.
3.5. Experiment 5 – Effects of lamotrigine on locomotion
The locomotion frequency is depicted in Fig. 4. Two-way ANOVA
revealed a signiﬁcant strain [F(1,36)=7.05; pb0.05] and treatment
effects [F(1,36)=4.18; pb0.05] and an interaction between these
factors [F(1,36)=5.06; pb0.05]. Post hoc analysis revealed that the
locomotion frequency was signiﬁcantly increased in SHR treated withFig. 1. Freezing response (s) of Wistar Rats (WR) and Spontaneously Hypertensive Rats
(SHR) acutely treated with two injections of saline (SAL) or 47.5 mg/kg lithium (LI).
#pb0.05 compared to WR of the same treatment. Two-way analysis of variance
followed by Duncan's test. Data are reported as mean±SE.saline when compared to WR with the same treatment. Lamotrigine
decreased the locomotion frequency of SHR when compared to SHR
treated with saline and WR treated with lamotrigine.
4. Discussion
The decrease in the performance of SHR in the CFC task observed in
this study corroborates our previous work (Calzavara et al., 2009).
Interestingly, although others have described memory deﬁcits in
some tasks using Wistar-Kyoto as controls (Hernandez et al., 2003;
Meneses et al., 2011), we have described that SHR did not present
deﬁcits in learning/memory tasks other than the CFC—as the
discriminative avoidance task (Calzavara et al., 2004) or locomotor
habituation in an open-ﬁeld (Calzavara et al., 2011)—when
compared to Wistar Rats (as in this and in our previous works). In
this sense, the deﬁcit in CFC seems to be related to disturbances in the
processing of emotional context and not to a general impairment in
learning/memory. This inability to process emotional information
(which would lead to a deﬁcit in the acquisition of CFC) could be
associated with some psychiatric disorders, such as schizophrenia or
bipolar disorder. Based on a previous extensive pharmacological
characterization, we suggested that the deﬁcit presented by SHR could
model the impairment in the emotional context processing related to
schizophrenia. Indeed, this deﬁcit was speciﬁcally reverted by antipsy-
chotics, potentiatedbyproschizophreniamanipulations (amphetamine,
ketamine and sleep deprivation—Becker et al., 2003; Herz and Melville,
1980; Janowsky and Risch, 1979), and not altered by acute treatment
with mood stabilizers (Calzavara et al., 2009). Nevertheless, in this
previous work we did not evaluate the effects of lithium, the prototype
mood stabilizer for the treatment of bipolar disorder, as well as the
effects of a repeated treatmentwith themood stabilizers. In this respect,Fig. 3. Freezing response (s) of Wistar Rats (WR) and Spontaneously Hypertensive Rats
(SHR) treated daily with saline (SAL) or 20 mg/kg lamotrigine (LA) during twenty days.
*pb0.05 compared to SAL group of the same strain; #pb0.05 compared to WR of the
same treatment. Two-way analysis of variance followed by Duncan's test. Data are
reported as mean±SE.
Table 1
Freezing response (s), jump and ﬂinch ofWistar (WR) and Spontaneously Hypertensive
Rats (SHR) treated with saline (SAL) or 20 mg/kg lamotrigine (LA) and submitted to the
training session of CFC task. *pb0.05 compared to SAL group of the same strain;
#pb0.05 compared to WR of the same treatment. Two-way analysis of variance
followed by Duncan's test. Data are reported as mean±SE.
Freezing time (s) Jump Flinch
WR SAL 37±11.9 1±0.44 1.3±0.36
WR LA 28±3.89 0.7±0.21 2±0.25
SHR SAL 13.8±4.21# 2.8±1 3.5±0.34#
SHR LA 16.7±4.93 1.2±0.62 2.4±0.45*
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observed after long-term treatment (reviewed by Amann et al., 2007;
Fountoulakis and Vieta, 2008).
In relation to lithium, the clinical literature suggests that this drug
is useful during the acute manic and the maintenance phase
(Fountoulakis and Vieta, 2008). Our data showed that neither an
acute nor a repeated treatment with lithium were able to ameliorate
the deﬁcit in CFC presented by SHR. In addition, they did not modify
the acquisition of CFC presented by WR, corroborating and extending
previous studies showing the absence of effect of a repeated lithium
treatment on the acquisition or expression of this conditioning
(Muraki et al., 1999; Tsaltas et al., 2007).
As reviewed elsewhere (Bowden, 2002), some studies show that
there is no acute antimaniac effect of lamotrigine. Our previous work
(Calzavara et al., 2009) demonstrated that acute treatment with
lamotrigine did not change the deﬁcit in CFC presented by SHR. The
present data show that a repeated treatment with this drug even
potentiated this deﬁcit, reinforcing the absence of a beneﬁcial effect of
mood stabilizer. Considering WR, the acute impairment in CFC
produced by lamotrigine observed in our previous work (Calzavara
et al., 2009) is not tolerated after a repeated treatment (present data).
As far as we know, this is the ﬁrst study addressing the effects of
lamotrigine on fear conditioning.
The decrease in fear conditioning after repeated treatment with
lamotrigine could be considered from different points of view. Firstly,
an antinociceptive action of lamotrigine (Gilron et al., 2006; Munro et
al., 2007) could interfere with the perception of the shock and,
therefore, impair the acquisition of the fear conditioning. Contrary to
this possibility, lamotrigine did not alter freezing time after the
presentation of the shock (experiment 4) in both Wistar and SHR.
Secondly, it could be suggested that this drug impairs the
acquisition of an emotional memory and this effect should be taken
into account when considering long-term treatment with this mood
stabilizer. On the other hand, clinical data indicate that lamotrigine
produces fewer untoward cognitive effects in healthy individuals and
bipolar patients when compared to other mood stabilizers (DabanFig. 4. Locomotion frequency of Wistar Rats (WR) and Spontaneously Hypertensive
Rats (SHR) treated with saline (SAL) or 20 mg/kg lamotrigine (LA). *pb0.05 compared
to SAL group of the same strain; # pb0.05 compared toWR of the same treatment. Two-
way analysis of variance followed by Duncan's test. Data are reported as mean±SE.et al., 2006; Meador et al., 2005; Shannon and Love, 2007). Indeed, the
effects of a lamotrigine monotherapy in emotional processing was
tested in bipolar disorder patients and the authors suggest that
lamotrigine treatment “may result in more efﬁcient processing of facial
affect for anger with reduction in ambiguity and “normalization” of the
pattern of activation” (Haldane et al., 2008). Conversely, based on our
results, we could speculate that in the case of the emotional processing
deﬁcits associated with schizophrenia, lamotrigine could instead be
harmful. In schizophrenia, lamotrigine has been used as an adjuvant
treatment. Nevertheless, a systematic review and meta-analysis
suggests that lamotrigine may be effective only for a substantial
proportionof patientswith clozapine-resistant schizophrenia (Tiihonen
et al., 2009).
Fromanother standpoint, this result couldbe related to the supposed
antidepressive effect of lamotrigine. Interestingly, differential analysis of
depressive and manic symptoms revealed that lamotrigine was
signiﬁcantly superior to placebo in prevention and time to intervention
of new depressive episodes, and reversely, lithium was better than
lamotrigine and both were better than placebo in prevention of manic
episodes (reviewed by Amann et al., 2007). In this way, long-term
antidepressive treatment promotes impairment in the acquisition of
CFC (Burghardt et al., 2004; Inoue et al., 1996, 2004; Santos et al., 2006).
Hence, in this study, the decreased acquisition of CFC in both WR and
SHR observed after long-term treatment with lamotrigine could be
related to the antidepressive proﬁle of this drug. In this respect, the
effects of lamotrigine could be interpreted as beneﬁcial. However, a
recent clinical paper pointed out that the antidepressive effect of
lamotrigine is not established yet (Calabrese et al., 2008).
Alternatively, mood stabilizers, such as carbamazepine, valproic
acid and lamotrigine, have been evaluated in clinical trials for a variety
of anxiety-related disorders, including posttraumatic stress disorder,
social phobia, obsessive–compulsive disorder and generalized anxiety
disorder (Berlin, 2007; Mula et al., 2007). In addition, an anxiolytic
effect of lamotrigine has been reported in animal models of anxiety
(Foreman et al., 2009). In this respect, it is well-established that
anxiolytic drugs impair the acquisition of fear conditioning (Brignell
and Curran, 2006; Calzavara et al., 2009; Fanselow and Helmstetter,
1988; Resstel et al., 2006). In this way, the decreased fear conditioning
induced by lamotrigine treatment could be related to its anxiolytic
effect.
From a methodological point of view, one might think that the
described hyperlocomotion presented by SHR (Calzavara et al., 2011;
Knardahl and Sagvolden, 1981; Van den Buuse and de Jong, 1989) could
interferewith the ability to freeze in this strain. Nonetheless, lamotrigine
decreased hyperlocomotion in SHR (experiment 5) without changing
freezing response to the shock (experiment 4). In addition, the
improvement in the CFC deﬁcit of SHR induced by antipsychotics
(Calzavara et al., 2009) is not accompanied by changes in their
hyperlocomotion (data not shown). It is also interesting to note that
SHR present a decreased freezing time in response to shock (as
previously observed for a loud noise—Hard et al., 1985) but their ﬂinch
response is enhanced (experiment 4). This seems to indicate that,
although they are able to perceive and react to the shock, this strain
might display different behaviors when submitted to aversive stimuli.
Importantly, although SHR exhibit a decrease in conditioned freezing
response, they are able to display this behavior (increase in freezing
response induced by previous exposure to the shock compared with
animals thatwere not exposed to this aversive stimulus—Calzavara et al.,
2009).
5. Conclusion
In conclusion, our data reinforce the absence of beneﬁcial effects of
mood stabilizers on the deﬁcit of CFC presented by SHR. From a clinical
point of view, both schizophrenia and bipolar disorder are associated
with emotional processing deﬁcits (Addington and Addington, 1998;
1611M.B. Calzavara et al. / Progress in Neuro-Psychopharmacology & Biological Psychiatry 35 (2011) 1607–1611Phillips et al., 2003). Considering the pharmacological therapeutic
treatment for these disorders, although antipsychotics are the ﬁrst-
choice treatment for schizophrenia and mood stabilizers are the most
common prescribed drugs for bipolar disorder, these drugs have been
employed to treat at least some aspects of both disorders (Chen et al.,
2007; Gao et al., 2005). Our data indicate that the impairment in
emotional context processing modeled by SHR seems to be sensitive
only to antipsychotics.
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